CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
BI 1323495,drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03802331
NCT03802331Phase 1Completed

Relative Bioavailability of BI 1323495 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)

Boehringer Ingelheim·interventional·Posted Jan 14, 2019·Updated Feb 22, 2024

In Brief

A Phase 1 clinical trial evaluating BI 1323495, for Healthy. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The main objective of this trial is to assess the effect of food on the pharmacokinetics of an oral tablet formulation of BI 1323495 by investigating the relative bioavailability following single dose administration under fed and fasted conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedJan 14, 2019
Enrollment StartJan 28, 2019
Primary CompletionMar 3, 2019
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 7.5 years ago

Interventions

BI 1323495,drug

single oral doses